Sherrif F Ibrahim1,2, Julia M Kasprzak3, Mary A Hall4, Alison L Fitzgerald4, Jennifer J Siegel4, Sarah J Kurley4, Kyle R Covington4, Matthew S Goldberg4,5, Aaron S Farberg6, Shannon C Trotter7, Kenneth Reed8, David G Brodland9, Shlomo A Koyfman10, Ally-Khan Somani11, Sarah T Arron12, Ashley Wysong13. 1. Rochester Dermatologic Surgery, Victor, NY 14564, USA. 2. Department of Dermatology, University of Rochester Medical Center, Rochester, NY 14620, USA. 3. Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI 53226, USA. 4. Castle Biosciences, Inc., Friendswood, TX 77546, USA. 5. Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY 10025, USA. 6. Department of Dermatology, Baylor University Medical Center, Dallas, TX 75246, USA. 7. Oakview Dermatology, Springfield, OH 45504, USA. 8. DermASAP, Quincy, MA 02169, USA. 9. Zitelli & Brodland, P.C., Pittsburgh, PA 15232, USA. 10. Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH 44106, USA. 11. Department of Dermatology, Indiana University School of Medicine, Indianapolis, IN 46202, USA. 12. Sarah Arron, P.C., San Mateo, CA 94115, USA. 13. Department of Dermatology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Abstract
Aim: To clinically validate the 40-gene expression profile (40-GEP) test for cutaneous squamous cell carcinoma patients and evaluate coupling the test with individual clinicopathologic risk factor-based assessment methods. Patients & methods: In a 33-site study, primary tumors with known patient outcomes were assessed under clinical testing conditions (n = 420). The 40-GEP results were integrated with clinicopathologic risk factors. Kaplan-Meier and Cox regression analyses were performed for metastasis. Results: The 40-GEP test demonstrated significant prognostic value. Risk classification was improved via integration of 40-GEP results with clinicopathologic risk factor-based assessment, with metastasis rates near the general cutaneous squamous cell carcinoma population for class 1 and ≥50% for class 2B. Conclusion: Combining molecular profiling with clinicopathologic risk factor assessment enhances stratification of cutaneous squamous cell carcinoma patients and may inform decision-making for risk-appropriate management strategies.
Aim: To clinically validate the 40-gene expression profile (40-GEP) test for cutaneous squamous cell carcinoma patients and evaluate coupling the test with individual clinicopathologic risk factor-based assessment methods. Patients & methods: In a 33-site study, primary tumors with known patient outcomes were assessed under clinical testing conditions (n = 420). The 40-GEP results were integrated with clinicopathologic risk factors. Kaplan-Meier and Cox regression analyses were performed for metastasis. Results: The 40-GEP test demonstrated significant prognostic value. Risk classification was improved via integration of 40-GEP results with clinicopathologic risk factor-based assessment, with metastasis rates near the general cutaneous squamous cell carcinoma population for class 1 and ≥50% for class 2B. Conclusion: Combining molecular profiling with clinicopathologic risk factor assessment enhances stratification of cutaneous squamous cell carcinoma patients and may inform decision-making for risk-appropriate management strategies.
Authors: Sarah T Arron; Ashley Wysong; Mary A Hall; Christine N Bailey; Kyle R Covington; Sarah J Kurley; Matthew S Goldberg; Julia M Kasprzak; Ally-Khan Somani; Sherrif F Ibrahim; David G Brodland; Nathan J Cleaver; Ian A Maher; Yang Xia; Shlomo A Koyfman; Jason G Newman Journal: Laryngoscope Investig Otolaryngol Date: 2022-01-06
Authors: Elahe Minaei; Simon A Mueller; Bruce Ashford; Amarinder Singh Thind; Jenny Mitchell; Jay R Perry; Benjamin Genenger; Jonathan R Clark; Ruta Gupta; Marie Ranson Journal: Front Oncol Date: 2022-04-11 Impact factor: 5.738